Evercore ISI Reiterates Buy Rating on ICON Public Limited Company
Evercore ISI Group has reiterated its buy rating on ICON with a price target of $180, a 5.97% upside from the current price.
Key Points
- Evercore ISI Group reiterated its buy rating for ICON Public Limited Company (ICLR) with a $180 price target on June 25, 2026.
- Evercore ISI Group's $180 price target implies 5.97% upside from ICON Public Limited Company's ($ICLR) current $169.86 share price.
- ICON shares traded near $158.17 on Thursday, with a market cap of about $10.78 billion and a forward P/E of 12.03.
- Insiders and analysts show mixed sentiment, with recent insider buys and sells, and varied analyst ratings from buy to sell.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Evercore ISI Group has reiterated its buy rating on ICON Public Limited Company (NasdaqGS: ICLR), maintaining a price target of $180. This reaffirmation came on June 25, 2026, as analyst Ross Muken expressed continued confidence in the company's prospects.
Evercore ISI Group vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
ICON Public Limited Company Stock Down 0.1%
Shares of NasdaqGS:ICLR traded near $158.17 on Thursday. ICON Public Limited Company boasts a market cap of approximately $10.78 billion. The stock has a P/E ratio of 48.36 and a forward P/E of 12.03, with a beta of 1.271. Over the past 52 weeks, the stock has ranged from $66.57 to $211.00, with a 50-day moving average of $124.49 and a 200-day moving average of $149.71. The company's current ratio stands at 1.096, and its quick ratio is 1.063, with a debt-to-equity ratio of 38.678.
$ICLR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its most recent financial results, ICON reported revenue of about $8.25 billion, reflecting a growth rate of 12.4%. The company's net margin is 2.78%, and it has a return on equity of 2.46%. Earnings per share (EPS) were reported at $2.91. ICON is expected to announce its next earnings results on June 23, 2026.
Insider Buying and Selling at ICON Public Limited Company
Recent insider activity at ICON Public Limited Company involved several transactions on May 14, 2026. Dr. John Climax bought and sold 5,005 shares, while Ronan Martin Murphy also executed both buying and selling of the same amount. Additionally, Eugene Pacelli McCague bought and sold 3,255 shares. These transactions were not part of any pre-arranged trading plans.
Analysts Set New Price Targets
On June 25, 2026, Evercore ISI Group maintained its buy rating on ICON with a price target of $180. On the same day, B of A Securities reiterated a sell rating with a $150 target, while Baird maintained a buy rating at $186. Previously, on June 24, 2026, Barclays maintained a hold rating with a $160 target. The consensus recommendation for ICON remains a buy, with an average target price of $154.19 among 16 analysts.
About ICON Public Limited Company
ICON Public Limited Company, headquartered in Dublin, Ireland, is a clinical research organization providing outsourced development and commercialization services. The company operates globally, offering clinical development, management, and analysis services across all phases of the clinical trial process. ICON serves the pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. Led by CEO Mr. Barry Balfe, ICON employs approximately 40,100 people worldwide.
Bottom Line
Evercore ISI's reaffirmation of its buy rating on ICON Public Limited Company reflects ongoing confidence in the company's strategic direction. Investors closely watch these analyst ratings as they often influence market perceptions. As a reminder, analyst reports like this are backward-looking reflections of the firm's analysis and may not indicate future performance.
Get ICON Public Limited Company alerts
New 13F filings, insider trades, and analyst moves on $ICLR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.